Research interests
A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans[8]
From 2018
Mark Paul Donahue
Fellow in Cardiology at Duke University
As of 2003 · Last known relationship
Fellow in Cardiology at Duke University
As of 2003 · Last known relationship
Mark Paul Donahue matters for cardiovascular research linking heart failure outcomes with genetics, biomarkers, mental health, and care delivery. He is an Associate Professor of Medicine in Duke’s Department of Medicine and trained at the University of Cincinnati, earning an M.D. in 1996 and completing residency from 1996 to 1999, followed by Duke cardiology fellowship training from 1999 to 2003. A 2022 Duke reflection records that he left fellowship a few months early to join the VA faculty in 2003. His documented research includes depression and heart failure progression, pharmacogenomic studies of beta-blocker benefit, cardiovascular risk reduction, proteomics, and Veterans Health Administration surveillance of myocarditis and pericarditis after COVID-19 vaccination.
Each topic is linked to its supporting source in Sources.
Training includes Fellow in Cardiology at Duke University, Medical Resident at University of Cincinnati, Joined the VA faculty in 2003 after leaving fellowship early, and Six-month Cath Lab rotation at the VA during Duke Cardiology Fellowship, plus 5 more records.
Explore education and trainingAs of 2003
As of 1999
As of 2003
As of 1999
Completed 1996
A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans[8]
From 2018
Depressive symptoms are associated with clinical outcomes in heart failure with reduced ejection fraction[8]
From 2024
Genetic Variation in Acid Ceramidase Predicts Non-completion of an Exercise Intervention[8]
From 2018
Genome-Wide Association Study of Beta-Blocker Survival Benefit in Black and White Patients with Heart Failure with Reduced Ejection Fraction[8]
From 2023
Grant for Depression and Heart Failure Disease Progression, awarded by the National Institutes of Health[8]
2014 to 2019
Grant for Genetics Myocardial Adverse Outcomes/Graft Failure-CABG (Gene-Magic), awarded by the National Institutes of Health[8]
2004 to 2011
Grant for the Integrated Program for Persons with Hemostatic Disorders, awarded by the Centers for Disease Control[8]
2001 to 2007
Grant for the Thrombosis and Hemostasis Centers Research and Prevention Network, awarded by the Centers for Disease Control and Prevention[8]
2002 to 2013
Incidence Rates and Clinical Characteristics of Patients With Confirmed Myocarditis or Pericarditis Following COVID-19 mRNA Vaccination: Experience of the Veterans Health Administration Through 9 October 2022[8]
From 2023
Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease: A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia[8]
From 2020
Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline[8]
From 2020
Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure[8]
From 2020
Same-day discharge among patients undergoing elective PCI: Insights from the VA CART Program[8]
From 2019
Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study[8]
From 2017